UMC Clinical Trials

Principal Investigator Category  Title of Protocol  Brief Description  Recruitment Contact

Agustin Garcia, MD

Oncology - Female Reproductive

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.

Additional Information

Research Phone
# 504-407-7395

Agustin Garcia, MD

Oncology - Breast

A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.

Additional Information

Research Phone
# 504-407-7395

Agustin Garcia, MD

Oncology - Cervical

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma.

Additional Information

Research Phone
# 504-407-7395

Agustin Garcia, MD

Oncology - Melanoma/Breast

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Breast

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Multiple

S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors Treatment with Ipilimumab and Nivolumab for Rare Cancers

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Breast/ Gynecologic

NRG-CC004 Phase Ii Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire In Women With Breast Or Gynecologic Cancer.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Melanoma

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Renal

S1500; A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Pancreatic

S1505; A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD

Oncology - Melanoma

EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.

Additional Information

Research Phone
# 504-407-7395

Augusto Ochoa, MD    

Oncology - Breast

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.

Additional Information

Research Phone
# 504-407-7395

Cindy Leissinger, MD

Hematology - Hemophilia

An Open-Label, Multicenter, Expanded Access Program For Emicizumab in Patents With Hemophilia and With Inhibitors.

Additional Information

Melody Benton:
mbenton@tulane.edu
or 504-988-3596

David Janz, MD

Pulmonology

VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment.

Additional Information

Paula Lauto:
plauto@lsuhsc.edu
or 504-568-4634

Frank Smart, MD

Cardiology

Medtronic Reveal LINQ Heart Failure Study                                   

Additional Information

Jacob Simon:
jsimo9@lsuhsc.edu
or 504-568-2349

Frank Smart, MD

Cardiology

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to
Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.

Additional Information

Jacob Simon:
jsimo9@lsuhsc.edu
or 504-568-2349

Frank Smart, MD

Cardiology

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)- EMPEROR-Preserved.

Additional Information

Jacob Simon:
jsimo9@lsuhsc.edu 
or 504-568-2349

Juzar Ali, MD

Pulmonology

An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment.

Additional Information

Maureen Vincent:
mvince@lsuhsc.edu
or 504-568-4581

Jyotsna Fuloria, MD

Oncology - Pancreatic 

A Phase II Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy

Additional Information

Shana Lennard:
shana.lennard@lcmchealth.org
or 504-702-5171

Jyotsna Fuloria, MD

Hematology - Sickle Cell

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease.

Additional Information

Shana Lennard:
shana.lennard@lcmchealth.org
or 504-702-5171

Jyotsna Fuloria, MD

Oncology - Relapsed of Refractory Multiple Myeloma and Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Additional Information

Shana Lennard:
shana.lennard@lcmchealth.org
or 504-702

Jyotsna Fuloria, MD

Oncology - Non-Small Cell Lung Cancer

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC.

Additional Information

Shana Lennard:
shana.lennard@lcmchealth.org
or 504-702

Kara De Felice, MD

Gastroenterology

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with the Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications.

Additional Information

Marie Sandi, FNP-BC:
mchild@lsuhsc.edu
or 504-568-3450

Matthew Lammi, MD

Pulmonology

TRITON: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study

Additional Information

Paula Lauto:
plauto@lsuhsc.edu
or 504-568-4634

Michael Hagensee, MD

Infectious Disease

ANCHOR: Anal Cancer/HSIL Outcomes Research Study

Additional Information

Cara Rowe, MSW: cjoh26@lsuhsc.edu
or 504-568-4640

Michael Hagensee, MD

Infectious Disease

SYN-078-301: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment

Additional Information

Cara Rowe, MSW:
cjoh26@lsuhsc.edu
or 504-568-4640

Michelle Loch, MD

Oncology - Breast

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo in Patients with HER-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane based Therapy (Main)

Additional Information

Research Phone
# 504-407-7395

Nathan Nielsen, MD

Pulmonolgy/Critical Care

LJ501-EAP01 EXPANDED ACCESS FOR LJPC-501

Additional Information

Nathan Nielsen, MD:
nnielsen@tulane.edu
or 504-988-3833

Oren Tessler, MD

Plastic Surgery

MTF 16-04-01: A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing, Prosthetic Acellular Dermal Matrix (ADM) Assisted Immediate Post-Mastectomy Breast Reconstruction.

Additional Information

Allison Fleury, RN:
afleur@lsuhsc.edu
or 504-903-9000

Patrick Greiffenstein, MD

Surgery

ACCUTE ATB-202 A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI)

Additional Information

Allison Fleury, RN: afleur@lsuhsc.edu
or 504-903-9000

Patrick Greiffenstein, MD

Surgery

An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure

Additional Information

Allison Fleury, RN:
afleur@lsuhsc.edu
or 504-903-9000

Reinhold Munker, MD

Oncology - Myeloma

Randomized Phase III Trial of Lenalidomide versus Observation Alone
in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Additional Information

Rachel Cruthirds:
rcruthir@tulane.edu

Reinhold Munker, MD

Oncology - Multiple

[766413-1] EAY131: Molecular Analysis for Therapy Choice (MATCH)

Additional Information

Rachel Cruthirds:
rcruthir@tulane.edu

Tammuella Singleton, MD

Hematology - Hemophilia

An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B

Additional Information

Melody Benton:
mbenton@tulane.edu
or 504-988-3596

Tammuella Singleton, MD

Hematology - Hemophilia

An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A.

Additional Information

Melody Benton:
mbenton@tulane.edu
or 504-988-3596

Thomas Reske, MD

Oncology - Liver

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as 2nd-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma.

Additional Information

Research Phone
# 504-407-7395

 

Our Partners

 

The Louisiana State University Health Sciences Center New Orleans has teaching, research, and health care functions state-wide, through its six professional schools and twelve Centers of Excellence, as well as the more than one hundred hospitals and other health science related institutions with which they maintain affiliations.

 

The second-oldest medical school in the Deep South and the 15th oldest medical school in the United States, Tulane School of Medicine is equipping the next generation of medical professionals with the tools to succeed in a rapidly changing world and shape the future of health care.